DUBLIN – To no one's great surprise, the underwriters of Genmab A/S's IPO on Nasdaq exercised their overallotment option, the company announced Friday, taking the total gross to $581.8 million. The Copenhagen-based antibody developer priced the offering of about 32.8 million American depositary shares at $17.75 Thursday. The stock (NASDAQ:GMAB) ended the week at $18.10. Read More
LONDON – Silence Therapeutics plc has finally secured a deal to transform its fortunes, signing up Mallinckrodt plc in a potential $693 million-per-asset collaboration to develop siRNA therapeutics that block the complement inflammatory cascade. Read More
Anorexia nervosa, Cynthia Bulik told BioWorld, has a long-term recovery rate of 25% and “the highest fatality rate of any psychiatric illness.” Those dismal statistics hint at the challenging nature of anorexia nervosa, but also at the shortcomings of current treatment options. Read More
Amarin Corp. plc's sale of $400 million in American depositary shares (ADSs) ahead of the Sept. 28 PDUFA date for Vascepa (icosapent ethyl) boosted investor confidence while sparking buzz about another player in the space: Acasti Pharma Inc., of Laval, Quebec, which has a krill oil-based product due to report pivotal data soon. Read More
HONG KONG – Celltrion Inc., of South Korea, and Hong Kong-based conglomerate Nan Fung Group Holdings Ltd. said they have built a joint venture named Vcell Healthcare Ltd., geared toward the Chinese market. Read More
Pharmaceutical and life sciences giant Bayer AG scored another indication for its MRI contrast agent, Gadavist (gadobutrol) injection, this time in adults with suspected coronary artery disease. The FDA nod makes Gadavist the first and only contrast agent approved for use in cardiac magnetic resonance (CMR) imaging. Read More
Janssen Pharmaceutical Co., a unit of New Brunswick, N.J.-based Johnson & Johnson, noted that the World Health Organization included Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer in the updated Essential Medicines List. Read More
Tonix Pharmaceuticals Holding Corp., of New York, said it closed an underwritten public offering of 9 million shares at 60 cents each, for total gross proceeds of approximately $5.4 million. Read More
Scientists from the Wellcome Trust Sanger Institute have shown that antioxidant treatment could reverse the competitive advantage of p53-mutated cells in the esophagus of transgenic mice. Read More
